US FDA’s Trump Transition Relatively Smooth, Except For Diversity, Equity Work
Several critical FDA drug activities can skirt early Trump administration directives, but trial diversity and health equity work may be hobbled.
Several critical FDA drug activities can skirt early Trump administration directives, but trial diversity and health equity work may be hobbled.